Oritavancin Serum Protein Binding for Bacterial Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections, particularly those caused by gram-positive organisms such as MRSA and vancomycin-resistant Enterococci, face challenges in achieving rapid and sustained bactericidal activity due to limitations in mechanisms of action and pharmacokinetic profiles of existing glycopeptide antibiotics.
Innovation Solution
Administering a therapeutically effective amount of oritavancin, a glycopeptide antibiotic, to achieve a specific range of serum protein binding (50% to 95%) to enhance its bactericidal activity and persistence, thereby targeting multiple mechanisms including cell wall synthesis inhibition, membrane disruption, and RNA synthesis inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional glycopeptide antibiotics are used to treat gram-positive infections, then bactericidal activity is achieved, but the rate of bactericidal activity is slow and sustained efficacy is limited
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of glycopeptide antibiotics by combining them with serum proteins to form complexes. This changes the binding characteristics and persistence in circulation, achieving both rapid bactericidal activity (within 15 minutes to 2 hours) and sustained efficacy over extended periods. The protein-bound form of oritavancin maintains stable concentrations in serum, prolonging the duration of action while preserving rapid killing capability.
2Duration of action of stationary object
If glycopeptide antibiotics bind to serum proteins, then persistence and distribution are improved, but the free fraction available for bactericidal activity may be reduced
Solution Approach 1:
Serum proteins act as intermediaries that facilitate the distribution and persistence of glycopeptide antibiotics in the circulation. The protein-bound complex serves as a reservoir that slowly releases active drug, maintaining both persistence and adequate free fraction for bactericidal activity. This intermediary binding mechanism resolves the contradiction by enabling prolonged circulation while preserving pharmacological activity through controlled release.
3Reliability
If multiple mechanisms of action are employed to enhance bactericidal activity, then treatment efficacy is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent employs a single glycopeptide antibiotic compound that inherently possesses multiple mechanisms of action: cell wall synthesis inhibition, membrane disruption, and RNA synthesis inhibition. This multi-functional agent achieves enhanced treatment efficacy without requiring combination therapies, thereby avoiding the complexity of multiple drug regimens. The single agent performs multiple functions simultaneously, resolving the contradiction between efficacy and regimen complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Oritavancin achieves rapid bactericidal activity and sustained efficacy by maintaining a high fraction bound to serum proteins, effectively targeting bacterial cell wall and membrane integrity, leading to enhanced treatment and prevention of bacterial infections.
Implementation Method 1
the effective amount of the glycopeptide antibiotic provides a fraction of glycopeptide antibiotic bound to serum proteins in the subject in the range of about 50% to about 95%
Implementation Method 2
inhibition of cell wall synthesis by both substrate-dependent and -independent mechanisms
Implementation Method 3
disruption of membrane potential and increasing membrane permeability
Data Source
AI summary
The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.